- Conditions
- Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
- Interventions
- SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
- Biological · Drug
- Lead sponsor
- BriaCell Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 200
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis C, Genotype 1
- Interventions
- Educational Intervention, Patient education and management skills training
- Procedure · Other
- Lead sponsor
- Chronic Liver Disease Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 43
- States / cities
- Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
- Conditions
- Chronic Hepatitis B
- Interventions
- hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN)
- Biological · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C, Chronic
- Interventions
- peginterferon alfa-2a [Pegasys], ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 7
- States / cities
- San Francisco, California • Farmington, Connecticut • Honolulu, Hawaii + 4 more
- Conditions
- Chronic Hepatitis C Infection, Fatty Liver
- Interventions
- Rosiglitazone and Pegasys/Ribavirin
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Essential Thrombocythemia
- Interventions
- INCA033989, Best Available Treatment
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 35 more
- Conditions
- Chronic Hepatitis B
- Interventions
- PEGASYS
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 820 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Downey, California • Los Angeles, California + 12 more
- Conditions
- Hepatitis C
- Interventions
- SOF, PEG, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- peg-IFN-α, Hematopoietic Cell Transplant (HCT), Tacrolimus, Methotrexate
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Hepatitis B
- Interventions
- NVR 3-778, Placebo for NVR 3-778, Pegasys
- Drug
- Lead sponsor
- Novira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Costa Mesa, California • Pasadena, California • San Diego, California + 1 more
- Conditions
- Liver Transplant, Hepatitis C
- Interventions
- Pegasys, Copegus
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Hepatitis C Virus Infection
- Interventions
- telaprevir, VX-222, ribavirin, peginterferon-alfa-2a
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- La Jolla, California • San Francisco, California • Aurora, Colorado + 16 more
- Conditions
- Hepatitis B
- Interventions
- Entecavir and peginterferon
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more
- Conditions
- Genotype 1 Chronic Hepatitis C, Treatment Naive
- Interventions
- Ribavirin, Telaprevir, Pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 34 more
- Conditions
- Hepatitis C, Chronic, Cirrhosis
- Interventions
- Telaprevir, Boceprevir, Peg-IFN, Ribavirin
- Drug
- Lead sponsor
- Louis Stokes VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hepatitis C, Chronic
- Interventions
- GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more
- Conditions
- Chronic Hepatitis C
- Interventions
- GS-5885, GS-9451, RBV, PEG
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 20 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more
- Conditions
- Hepatitis C
- Interventions
- INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Anaheim, California • La Jolla, California • San Francisco, California + 3 more
- Conditions
- Hepatitis C, Genotype 1
- Interventions
- Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more
- Conditions
- Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more
- Conditions
- Leukemia, Myeloid, Philadelphia-Positive
- Interventions
- PEG-Intron
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pediatric Immuno-Tolerant Chronic Hepatitis B
- Interventions
- Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 3
- States / cities
- Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania